Join Dr. Heather Snyder, VP Medical and Scientific Relations, and Dr. Claire Sexton, Director of Scientific Programs & Outreach, for an Alzheimer’s Association Webinar to learn about the latest developments in Alzheimer’s and dementia science. The talk will be on Tuesday May 4 from 1:30 to 3:00 p.m. To register, click on the link below. You will then receive a zoom link on May 4.
A treatment where surgeons implant a tiny device in the retinas of patients which contain stem cells looks extremely promising for those with age-related macular degeneration (AMD). Although it has only been done with 15 patients, many participants have passed the one-year mark with improving vision. One woman who had the treatment said, “Shortly after the surgery, I turned to my husband while we were watching TV and said, ‘I can see all of their faces!’” Doctors say FDA approval is about five years away. To see local specialists in macular degeneration, see links below.
There has been so much bad news on the Alzheimer’s front, it was refreshing to read that an experimental treatment from Eli Lilly & Company helped patients. Granted, it was a small trial of 272 people with mild Alzheimer’s disease, but results show that donanemab met the primary goal of the study, slowing the decline in memory and the ability to perform activities of daily living by 32% over an 18-month period. Lilly is so excited about the results that it started enrolling another 500 subjects for a new study to confirm the findings.